keyword
MENU ▼
Read by QxMD icon Read
search

Everolimus

keyword
https://www.readbyqxmd.com/read/27911276/the-mtor-inhibitor-everolimus-in-combination-with-azacitidine-in-patients-with-relapsed-refractory-acute-myeloid-leukemia-a-phase-ib-ii-study
#1
Peter Tan, Ing Soo Tiong, Shaun Fleming, Giovanna Pomilio, Nik Cummings, Mark Droogleever, Julie McManus, Anthony Schwarer, John Catalano, Sushrut Patil, Sharon Avery, Andrew Spencer, Andrew Wei
Therapeutic options are limited in relapsed/refractory acute myeloid leukemia (AML). We evaluated the maximum tolerated dose (MTD) and preliminary efficacy of mammalian target of rapamycin (mTOR) inhibitor, everolimus (days 5-21) in combination with azacitidine 75 mg/m2 subcutaneously (days 1-5 and 8-9 every 28 days) in 40 patients with relapsed (n = 27), primary refractory (n = 11) or elderly patients unfit for intensive chemotherapy (n = 2). MTD was not reached following everolimus dose escalation (2.5, 5 or 10 mg; n = 19) to the 10 mg dose level which was expanded (n = 21)...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27909994/cabozantinib-a-review-in-advanced-renal-cell-carcinoma
#2
Zaina T Al-Salama, Gillian M Keating
The multiple tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx™) is approved in the USA for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the EU, cabozantinib is indicated for the treatment of advanced RCC in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. In adults with advanced or metastatic clear-cell RCC who had previously received VEGF receptor (VEGFR) TKIs, progression-free survival (PFS) and overall survival (OS) were significantly prolonged in patients who received oral cabozantinib versus oral everolimus in the pivotal METEOR trial...
December 1, 2016: Drugs
https://www.readbyqxmd.com/read/27906072/actrii-blockade-protects-mice-from-cancer-cachexia-and-prolongs-survival-in-the-presence-of-anti-cancer-treatments
#3
Shinji Hatakeyama, Serge Summermatter, Marie Jourdain, Stefan Melly, Giulia C Minetti, Estelle Lach-Trifilieff
BACKGROUND: Cachexia affects the majority of patients with advanced cancer and is associated with reduced treatment tolerance, response to therapy, quality of life, and life expectancy. Cachectic patients with advanced cancer often receive anti-cancer therapies against their specific cancer type as a standard of care, and whether specific ActRII inhibition is efficacious when combined with anti-cancer agents has not been elucidated yet. METHODS: In this study, we evaluated interactions between ActRII blockade and anti-cancer agents in CT-26 mouse colon cancer-induced cachexia model...
July 26, 2016: Skeletal Muscle
https://www.readbyqxmd.com/read/27904650/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-clinical-trial-evidence-and-experience
#4
REVIEW
Jose Manuel Ruiz-Morales, Daniel Y C Heng
The treatment of metastatic renal cell carcinoma (mRCC) is rapidly changing. During first-line treatment with targeted therapy, patients ultimately develop resistance to therapy and the disease progresses. Recently, cabozantinib has demonstrated a better response rate, progression-free survival and overall survival compared with everolimus after failure of prior targeted therapy in patients with advanced or metastatic renal cell carcinoma (RCC). Cabozantinib is a small-molecule tyrosine kinase inhibitor (TKI)...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27903028/-cardiovascular-morbidity-and-mortality-in-patients-with-kidney-disease
#5
Ivo Quack, Ralf Westenfeld
Patients with kidney disease have a significantly increased cardiovascular morbidity and mortality. Especially diabetics have an increased risk to develop renal insufficiency and cardiovascular events. Two recent studies show that the SGLT2 inhibitor Empagliflozin and the GLP1 agonist Liraglutid are able to lower the cardiovascular risk of type2 diabetics with renal insufficiency. Recent observations suggest that bradycardia and asystole are main triggers for sudden cardiac death in patients with chronic kidney disease...
November 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27896917/on-the-pathogenesis-of-mtor-associated-stomatitis-mias-studies-using-an-organotypic-model-of-the-oral-mucosa
#6
Stephen Sonis, Paulette Wright Andreotta, Gregory Lyng
OBJECTIVE: mTOR inhibitor treatment of solid cancers is associated with mTOR inhibitor-associated stomatitis (mIAS) a common, significant, dose-limiting toxicity, with aphthous-like lesions. Our objective was to assess the utility of a new organotypic model in defining mIAS' pathogenesis. MATERIALS AND METHODS: The effect of everolimus on organotypic human oral mucosa was studied. Sterile specimens were assessed 24 hr and 48 hr after exposure to varying concentrations of everolimus...
November 29, 2016: Oral Diseases
https://www.readbyqxmd.com/read/27896897/expanded-clinical-use-of-everolimus-eluting-bioresorbable-vascular-scaffolds-for-treatment-of-coronary-artery-disease
#7
Roberto Diletti, Yuki Ishibashi, Cordula Felix, Yoshinobu Onuma, Shimpei Nakatani, Nicolas M van Mieghem, Eveliyn Regar, Marco Valgimigli, Peter P de Jaegere, Nienke van Ditzhuijzen, Jiang Ming Fam, Jurgen M R Ligthart, Mattie J Lenzen, Patrick W Serruys, Felix Zijlstra, Robert Jan van Geuns
BACKGROUND: Limited data are currently available on the performance of everolimus eluting bioresorbable vascular scaffold (BVS) for treatment of complex coronary lesions representative of daily practice. METHODS: This is a prospective, mono-center, single-arm study, reporting data after BVS implantation in patients presenting with stable, unstable angina, or non-ST segment elevation myocardial infarction caused by de novo stenotic lesions in native coronary arteries...
November 29, 2016: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/27894335/everolimus-and-exemestane-in-long-survival-hormone-receptor-positive-male-breast-cancer-case-report
#8
Z Ballatore, M Pistelli, N Battelli, A Pagliacci, M De Lisa, R Berardi, S Cascinu
BACKGROUND: Male breast cancer is a rare event, accounting for approximately 1% of all breast carcinomas. Although men with breast cancer had poorer survival when compared with women, data on prognosis principally derive from retrospective studies and from extrapolation of female breast cancer series. We reported the case of a very long survival patient. CASE PRESENTATION: A caucasian 42-year-old man underwent radical mastectomy with axillary dissection for breast cancer in 1993...
November 28, 2016: BMC Research Notes
https://www.readbyqxmd.com/read/27893038/targeting-the-pi3k-akt-mtor-pathway-for-the-treatment-of-mesenchymal-triple-negative-breast-cancer-evidence-from-a-phase-1-trial-of-mtor-inhibition-in-combination-with-liposomal-doxorubicin-and-bevacizumab
#9
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, Thorunn Helgason, Daniel D Karp, Funda Meric-Bernstam, Kenneth R Hess, Shelley M Herbrich, Vicente Valero, Constance Albarracin, Jennifer K Litton, Mariana Chavez-MacGregor, Nuhad K Ibrahim, James L Murray, Kimberly B Koenig, David Hong, Vivek Subbiah, Razelle Kurzrock, Filip Janku, Stacy L Moulder
Importance: Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27890494/neuroendocrine-tumors-of-the-lung-current-challenges-and-advances-in-the-diagnosis-and-management-of-well-differentiated-disease
#10
REVIEW
Andrew E Hendifar, Alberto M Marchevsky, Richard Tuli
Neuroendocrine tumors (NET) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs and gastrointestinal tract. Lung NET can be classified as well-differentiated (low-grade typical carcinoids [TC] and intermediate-grade atypical carcinoids [AC]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma or small cell lung carcinoma). The incidence of these tumors is increasing, but disease awareness remains low among thoracic specialists who are often involved in the diagnosis and early treatment for these patients...
November 23, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27887689/usefulness-of-post-coronary-dilation-to-prevent-recurrent-myocardial-infarction-in-patients-treated-with-percutaneous-coronary-intervention-for-acute-coronary-syndrome-from-the-base-acs-trial
#11
Pasi P Karjalainen, Matti Niemelä, Mika Laine, Juhani K E Airaksinen, Antti Ylitalo, Wail Nammas
Stent underexpansion is associated with worse outcome after stent implantation. Whether post-dilation (PD) improves outcome in patients with acute coronary syndrome (ACS) remains unclear. We performed post hoc analysis of outcome in patients from the BASE ACS (A prospective randomized comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome) trial who underwent PD versus those who did not. The BASE ACS trial randomized 827 patients (1:1) with ACS to receive either titanium-nitride-oxide-coated bioactive stents or everolimus-eluting stents...
November 1, 2016: American Journal of Cardiology
https://www.readbyqxmd.com/read/27883943/targeted-therapy-for-breast-cancer-and-molecular-mechanisms-of-resistance-to-treatment
#12
REVIEW
Guowei Gu, Derek Dustin, Suzanne Aw Fuqua
In recent years, clinical trials investigating new drugs and therapeutic combinations have led to promising advances in breast cancer therapy. Subtyping breast cancers into hormone receptor (HR) positive, epidermal growth factor receptor (HER2) positive, and triple negative breast cancer (TNBC) is currently the basis of diagnosing and treating this disease. In addition to endocrine and HER2-targeted therapies in their respective subtypes, evidence from recent preclinical studies have shown several targetable pathways that overcome resistance in the clinical setting...
November 21, 2016: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/27879518/three-month-evaluation-of-strut-healing-using-a-novel-optical-coherence-tomography-analytical-method-following-bioresorbable-polymer-everolimus-eluting-stent-implantation-in-humans-the-timeless-study
#13
Boris Vesga, Hector Hernandez, Miguel Moncada, Pawel Gasior, Sergio A H Leal, Antonio Dager, Camilo Arana, Juan A Delgado, Philippe Généreux, Akiko Maehara, Juan F Granada
AIMS: Bioresorbable polymer drug-eluting stent technologies have been considered to have the potential to enhance vascular healing by reducing polymer exposure to the vessel wall, potentially allowing the earlier discontinuation of dual antiplatelet therapy. At present, the early vascular healing response to this type of technologies is still unclear. PATIENTS AND METHODS: The TIMELESS study is a multicenter, prospective, single-arm study that enrolled real-world patients undergoing percutaneous coronary intervention...
November 22, 2016: Coronary Artery Disease
https://www.readbyqxmd.com/read/27878332/accelerated-cardiac-rhabdomyoma-regression-with-everolimus-in-infants-with-tuberous-sclerosis-complex
#14
Fatou Aw, Isabelle Goyer, Marie-Josée Raboisson, Christine Boutin, Philippe Major, Nagib Dahdah
Tuberous sclerosis complex is associated with benign tumors such as cardiac rhabdomyomas (RHM) caused by the disinhibition of the mammalian target of rapamycin (mTOR) protein. Recent reports on everolimus, an mTOR inhibitor, have shown size reduction of RHM. We compared cases recently treated with everolimus to historic controls whose first echocardiography was within first month of life. The largest dimension of the largest RHM was reported as a percentage compared to the earliest echocardiography study. Treatment of the four cases was started at a median age of 6...
November 23, 2016: Pediatric Cardiology
https://www.readbyqxmd.com/read/27870581/everolimus-in-patients-with-advanced-follicular-derived-thyroid-cancer-results-of-a-phase-ii-clinical-trial
#15
T C Schneider, D de Wit, T P Links, N P van Erp, J J M van der Hoeven, H Gelderblom, C F M Roozen, M Bos, W E Corver, T van Wezel, J W A Smit, H Morreau, H J Guchelaar, E Kapiteijn
BACKGROUND: mTOR upregulation has been reported to be involved in the pathogenesis of thyroid tumors and treatment with the mTOR inhibitor everolimus has shown promising results in endocrine tumors. We conducted a prospective phase II clinical trial to determine the efficacy and safety of everolimus in patients with advanced differentiated thyroid cancer. PATIENTS AND METHODS: Twenty-eight patients with progressive metastatic or locally advanced radioactive refractory differentiated thyroid cancer and 7 patients with anaplastic thyroid cancer were included and received everolimus 10mg orally once daily...
November 21, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27866134/one-year-clinical-outcomes-of-patients-treated-with-everolimus-eluting-bioresorbable-vascular-scaffolds-versus-everolimus-eluting-metallic-stents-a-propensity-score-comparison-of-patients-enrolled-in-the-absorb-extend-and-spirit-trials
#16
José de Ribamar Costa, Alexandre Abizaid, Antonio L Bartorelli, Robert Whitbourn, Nigel Jepson, Marco Perin, Clemens Steinwender, Marrianne Stuteville, Divine Ediebah, Krishnankutty Sudhir, Patrick W Serruys
AIMS: We sought to compare the outcomes of low/moderate complexity patients treated with the Absorb BVS from the ABSORB EXTEND trial with patients treated with the XIENCE everolimus-eluting stent (EES), using propensity score (PS) matching of pooled data from the SPIRIT trials (SPIRIT II, SPIRIT III, SPIRIT IV) and the XIENCE V USA trial. METHODS AND RESULTS: ABSORB EXTEND was a prospective, single-arm, open-label clinical study in which 812 patients were enrolled at 56 sites...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27866129/long-term-outcomes-after-resolute-zotarolimus-eluting-stent-implantation-in-patients-with-st-segment-elevation-acute-myocardial-infarction-insights-from-the-resolute-all-comers-trial-and-the-resolute-global-clinical-trial-program
#17
Carlo Di Mario, Patrick W Serruys, Sigmund Silber, Shuzheng Lu, Weimin Wang, Petr Widimský, Bo Xu, Stephan Windecker
AIMS: We examined long-term outcomes after implantation of the Resolute zotarolimus-eluting stent (R-ZES) in ST-segment elevation acute myocardial infarction (STEMI) patients. METHODS AND RESULTS: We compared long-term outcomes of STEMI patients undergoing primary angioplasty <12 hours from symptom onset who were randomised to the R-ZES (n=122) or the everolimus-eluting stent (EES, n=158) in the RESOLUTE All Comers Trial after propensity score adjustment. The five-year cumulative incidence of target lesion failure (TLF) was 7...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27864574/enhancing-endocrine-therapy-combination-strategies-for-the-treatment-of-postmenopausal-hormone-receptor-positive-her2-advanced-breast-cancer
#18
REVIEW
Kathleen I Pritchard, Stephen K Chia, Christine Simmons, Deanna McLeod, Alexander Paterson, Louise Provencher, Daniel Rayson
: : Breast cancer (BC) is the most common malignancy in women worldwide, with approximately two-thirds having hormone receptor (HR)-positive tumors. New endocrine therapy (ET) strategies include combining ET agents as well as adding inhibitors targeting growth factors, angiogenesis, the mechanistic target of rapamycin, phosphoinositide 3-kinase (PI3K), or cyclin-dependent kinase 4/6 to ET. Level 1 evidence supports use of fulvestrant plus anastrozole or palbociclib plus letrozole as first-line therapy for HR-positive, HER2-negative advanced BC with special consideration for the former in ET-naïve patients, as well as everolimus plus exemestane or palbociclib plus fulvestrant as second-line therapy with special consideration in select first-line patients...
November 18, 2016: Oncologist
https://www.readbyqxmd.com/read/27863441/sulforaphane-inhibits-proliferation-and-invasive-activity-of-everolimus-resistant-kidney-cancer-cells-in-vitro
#19
Eva Juengel, Sebastian Maxeiner, Jochen Rutz, Saira Justin, Frederik Roos, Wael Khoder, Igor Tsaur, Karen Nelson, Wolf O Bechstein, Axel Haferkamp, Roman A Blaheta
Although the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, has improved the outcome of patients with renal cell carcinoma (RCC), improvement is temporary due to the development of drug resistance. Since many patients encountering resistance turn to alternative/complementary treatment options, an investigation was initiated to evaluate whether the natural compound, sulforaphane (SFN), influences growth and invasive activity of everolimus-resistant (RCCres) compared to everolimus-sensitive (RCCpar) RCC cell lines in vitro...
November 17, 2016: Oncotarget
https://www.readbyqxmd.com/read/27862865/long-term-clinical-and-angiographic-outcomes-of-percutanenous-coronary-intervention-with-everolimus-eluting-stents-for-the-treatment-of-cardiac-allograft-vasculopathy
#20
Richard Cheng, Christopher Vanichsarn, Jignesh K Patel, Jesse Currier, David H Chang, Michelle M Kittleson, Raj Makkar, Jon A Kobashigawa, Babak Azarbal
BACKGROUND: Percutaneous coronary intervention (PCI) with bare-metal and first-generation drug-eluting stents (DES) for cardiac allograft vasculopathy (CAV) is associated with unexpectedly high restenosis rates and target lesion revascularization (TLR). Long-term outcomes of stenting for CAV using second-generation everolimus-eluting stents (EES) are not established. OBJECTIVE: To evaluate clinical and angiographic outcomes of CAV stenting with EES. METHODS: Patients who underwent PCI with EES for CAV were studied...
November 10, 2016: Catheterization and Cardiovascular Interventions
keyword
keyword
932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"